PROFESSIONAL INFORMATION FOR MEDICINES FOR HUMAN USE

Sinuforce Formula

COMPLEMENTARY MEDICINE

Homeopathic Medicines

This unregistered medicine has not been evaluated by the South African Health Products Regulatory Authority for its quality, safety or intended use.

SCHEDULING STATUS

S0

1 NAME OF THE MEDICINE

A.VOGEL SINUFORCE FORMULA (oral drops)
Homeopathic Complex

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml contains:

Cinnabar (Cinnabaris)	D8	.....0,2 ml
Hydrastis canadensis L. *(Hydrastis canadensis)*	D6	.....0,2 ml
Lemna minor L. *(Lemna minor)*	D3	.....0,2 ml
Luffa operculata (L.) Cogn. *(Luffa operculata)*	D6	.....0,2 ml
Potassium dichromate *(Kalium bichromicum)*	D6	.....0,2 ml

Contains approximately 50 % *v/v* alcohol.
Sugar free.

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Clear, colourless liquid with an aromatic odour and taste.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

A.VOGEL SINUFORCE FORMULA is a homeopathic medicine for the supportive treatment of nasal congestion and catarrh. In accordance with homeopathic literature, ingredients address symptoms associated with congestion of the nasal passages, such as headache, postnasal drip, runny nose and mucous build-up.

4.2 Posology and method of administration

Posology

Adults and children over 12 years:
Take 10 drops 3 – 4 times daily.
In acute/severe cases:
Take 10 drops hourly, gradually reducing frequency as improvement occurs, or as directed by a doctor, pharmacist or other healthcare provider.

Special populations

Elderly population:
No dosage adjustment is required for this population.

Paediatric population:
Children 6 – 12 years:
Take 5 drops 3 – 4 times daily.
Children 2 – 6 years:
Take 2 drops 3 – 4 times daily.
In acute/severe cases:
Take the relevant number of drops, as specified above for the child's age category, hourly, gradually reducing frequency as improvement occurs, or as directed by a doctor, pharmacist or other healthcare provider.

Method of administration

For oral use only.
Take drops on the tongue, or directly under the tongue, or in a teaspoon of water.
Take 15 minutes before meals.
Discontinue once improvement occurs.

4.3 Contraindications

- A.VOGEL SINUFORCE FORMULA should not be used in patients who have a hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

- A.VOGEL SINUFORCE FORMULA contains alcohol and should be used with caution by individuals with a sensitivity or intolerance to alcohol.
- If symptoms last longer than 7 days or are associated with fever (above 38 °C), please consult a doctor, pharmacist or other healthcare provider.

Paediatric population

- A.VOGEL SINUFORCE FORMULA, (due to its alcohol content) may impact sensitive individuals during daily activities such as learning ability, physical activities, or affect appetite or sleep patterns.

4.5 Interaction with other medicines and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females
No information available.

Pregnancy

No information available.
Although no specific safety studies on the use of A.VOGEL SINUFORCE FORMULA in pregnancy have been conducted, homeopathic remedies are generally considered to be suitable for use during pregnancy, however, please consult your doctor, pharmacist or healthcare provider for further advice.

Breastfeeding

No information available.
Although no specific safety studies on the use of A.VOGEL SINUFORCE FORMULA in breastfeeding have been conducted, homeopathic remedies are generally considered to be suitable for use during breastfeeding, however, please consult your doctor, pharmacist or healthcare provider for further advice.

Fertility

No effect on fertility expected.

4.7 Effects on ability to drive and use machines

A.VOGEL SINUFORCE FORMULA, (due to its alcohol content) may have an effect on mental and/or physical abilities to perform or execute tasks or activities requiring mental alertness, judgment and/or sound coordination and vision in sensitive individuals.

4.8 Undesirable effects

If symptoms of hypersensitivity occur e.g. rash, urticaria or angioedema of the skin, discontinue use of product, and contact your healthcare professional immediately.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the "**6.04 Adverse Drug Reaction Reporting Form**", found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8

4.9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity (see section 4.8).
Treatment of overdose should be symptomatic and supportive.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Homeopathy D33.2
Has traditionally been used according to homeopathic principles.

5.2 Pharmacokinetic properties

No information available.

5.3 Preclinical safety data

No information available.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Contains approximately 50 % *v/v* alcohol.

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
60 months.

6.4 Special precautions for storage
Store at or below 25 °C.
Protect from light.
Store in the original package/container.

6.5 Nature and contents of container
Packed in an amber type III glass bottle, with plastic dropper (LDPE) and screw cap (HDPE) with tamper evident seal.

Pack size: 30 ml

6.6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product
No special requirements.

7 THE HOLDER OF THE CERTIFICATE OF REGISTRATION
PharmaForce (Pty) Ltd.
130 – 16th Road
Midrand, 1685
South Africa
+27 (0)10 020 2520
www.avogel.co.za

Manufacturer:
CoMED Health (Pty) Ltd.
313 Kuit Street
Pretoria, 0184
South Africa

8 REGISTRATION NUMBER(S)/REFERENCE NUMBER
U 662 (Act 101/1965)

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
To be allocated.

10 DATE OF REVISION OF TEXT
July 2021